Related Experiment Videos
Recombinant antibody constructs in cancer therapy
1Cooperative Research Centre for Diagnostic Technologies, The Commonwealth Scientific and Industrial Research Organisation, MolecularScience Unit, 343 Royal Parade, Parkville, Victoria, 3052, Australia. peter.hudson@molsci.csiro.au
Current Opinion in Immunology
|October 6, 1999
Summary
Engineered antibodies are revolutionizing cancer therapy and diagnosis, with new designs and selection methods yielding high-affinity reagents for targeted treatments and improved immune responses.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Immunology and Cancer Research
Background:
- Recombinant antibodies and fragments constitute over 30% of proteins in clinical trials.
- Recent FDA approval highlights engineered antibodies for therapeutic applications.
- Antibodies are increasingly recognized as key reagents for cancer targeting.
Purpose of the Study:
- To review recent advances in engineered antibody design, selection, and production.
- To highlight innovative applications of engineered antibodies in cancer diagnosis and therapy.
- To discuss the role of bispecific antibodies in cancer immunotherapy.
Main Methods:
- Development of innovative antibody selection methods.
- Engineering of antibody fragments for fusion with various payloads (radioisotopes, drugs, toxins, enzymes, biosensors).
- Production of bispecific antibodies and related fusion proteins.
Main Results:
- Isolation of high-affinity cancer-targeting and antiviral antibodies.
- Successful fusion of antibody fragments with diagnostic and therapeutic payloads.
- Development of bispecific antibodies enhancing anti-cancer immune responses.
Conclusions:
- Engineered antibodies represent a significant advancement in cancer diagnosis and therapy.
- Novel selection and engineering strategies are expanding the utility of antibodies.
- Bispecific antibodies show promise for enhancing cancer immunotherapy and T cell recruitment.